A Post Covid-19 Invasive Renal Mucormycosis with acute renal failure; a case report and review of literature

Post Covid-19 Invasive Renal Mucormycosis with acute renal failure; a case report and review of literature

Authors

  • Farzanarasheednarejo Sindh insititute of urology and transplanatation,Karachi, Sindh,Pakistan https://orcid.org/0009-0009-2708-7955
  • Asma Naseem Sindh Institute of Urology Transplantation, SIUT, Karachi. Pakistan
  • Nazar ul Islam Jafri Sindh Institute of Urology Transplantation, SIUT, Karachi. Pakistan
  • Shaheera Shakeel Sindh Institute of Urology Transplantation, SIUT, Karachi. Pakistan
  • Syed Fazal Akhtar Sindh Institute of Urology Transplantation, SIUT, Karachi. Pakistan

DOI:

https://doi.org/10.53778/pjkd82255

Keywords:

Mucor Mycosis, Acute Kidney Injury , COVID-19,, Amphotericin

Abstract

Abstract: The worst nightmare of twenty first century has been discoverd, The Coronavirus, has been  risen the  incidence of  mucormycosis during the( COVID-19) pandemic. There  are many case reports of rhinoorbito-cerebral and pulmonary mucormycosis. Hypertension, COVID, and mucormycosis are lethal combination associated with high mortality.  This is the first case of Covid-19 associated mucormycosis (CAM) in the kidneys from Pakistan. We report the case of a 68-years old woman who presented with fever, abdominal pain and renal failure. Mucormycosis was diagnosed on renal biopsy. She was managed with Amphotericin- B and hemodialysis via tunneled vascular catheter. She refused nephrectomy. The case highlighted CAM can present as localized renal mucormycosis. In this era of Covid pandemic CAM should be in the differential diagnosis

Author Biography

Farzanarasheednarejo, Sindh insititute of urology and transplanatation,Karachi, Sindh,Pakistan

Assistant professor of nephrology, SIUT, Karachi, Sindh, Pakistan.

References

Baqi S, Naz A, Sayeed MA, et al. Clinical Characteristics and Outcome of Patients With Severe COVID-19 Pneumonia at a Public Sector Hospital in Karachi, Pakistan. Cureus. 2021;13(2):e13107.

Rudramurthy SM, Hoenigl M, Meis JF, et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses. 2021;64(9):1028-1037.

Tayabali K, Pothiwalla H, Narayanan S. Epidemiology of COVID-19-Associated Mucormycosis. Curr Fungal Infect Rep. 2023:1-20.

Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022;3(7):e543-e552.

Ozbek L, Topcu U, Manay M, et al. COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases. Clin Microbiol Infect. 2023;29(6):722-731.

Walther G, Wagner L, Kurzai O. Updates on the Taxonomy of Mucorales with an Emphasis on Clinically Important Taxa. J Fungi (Basel). 2019;5(4).

Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54 Suppl 1(Suppl 1):S16-22.

Tamez-Perez HE, Quintanilla-Flores DL, Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Tamez-Pena AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes. 2015;6(8):1073-1081.

Perricone C, Bartoloni E, Bursi R, et al. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunol Res. 2020;68(4):213-224.

Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-e421.

Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol. 2011;49(6):2151-2153.

Downloads

Published

2024-06-30